Luage, Maria Luz .
HRN: 22-47-23 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/12/2023
CO-AMOXICLAV 625MG (TAB)
01/12/2023
01/19/2023
ORAL
625
BID
Nka
Waiting Final Action
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes